American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
- PMID: 17954709
- DOI: 10.1200/JCO.2007.14.2364
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Abstract
Purpose: To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer.
Methods: For the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee's literature review focused attention on available systematic reviews and meta-analyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations. Recommendations and
Conclusions: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline. The following categories showed evidence of clinical utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays. Not all applications for these markers were supported, however. The following categories demonstrated insufficient evidence to support routine use in clinical practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells.
Comment in
-
Reaction to American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol. 2008 Apr 20;26(12):2057-8; author reply 2060-1. doi: 10.1200/JCO.2007.15.5614. J Clin Oncol. 2008. PMID: 18421062 No abstract available.
-
Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.J Clin Oncol. 2008 Apr 20;26(12):2058-9; author reply 2060-1. doi: 10.1200/JCO.2007.15.6638. J Clin Oncol. 2008. PMID: 18421063 No abstract available.
Similar articles
-
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858339 Free PMC article. Review.
-
Biomarkers for the clinical management of breast cancer: international perspective.Int J Cancer. 2013 Jul;133(1):1-13. doi: 10.1002/ijc.27997. Epub 2013 Feb 8. Int J Cancer. 2013. PMID: 23280579 Review.
-
Age-associated biomarker profiles of human breast cancer.Int J Biochem Cell Biol. 2002 Nov;34(11):1318-30. doi: 10.1016/s1357-2725(02)00052-3. Int J Biochem Cell Biol. 2002. PMID: 12200028
-
Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.J Clin Oncol. 1996 Oct;14(10):2843-77. doi: 10.1200/JCO.1996.14.10.2843. J Clin Oncol. 1996. PMID: 8874347
-
[Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].Geburtshilfe Frauenheilkd. 1996 Apr;56(4):177-83. doi: 10.1055/s-2007-1022256. Geburtshilfe Frauenheilkd. 1996. PMID: 8682282 German.
Cited by
-
Quantum dots: The trailblazers of early detection.J Oral Maxillofac Pathol. 2024 Jan-Mar;28(1):100-105. doi: 10.4103/jomfp.jomfp_377_23. Epub 2024 Apr 15. J Oral Maxillofac Pathol. 2024. PMID: 38800429 Free PMC article. Review.
-
Hypomethylation of ATP1A1 Is Associated with Poor Prognosis and Cancer Progression in Triple-Negative Breast Cancer.Cancers (Basel). 2024 Apr 25;16(9):1666. doi: 10.3390/cancers16091666. Cancers (Basel). 2024. PMID: 38730618 Free PMC article.
-
Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies.Nanoscale Adv. 2024 Apr 10;6(9):2270-2286. doi: 10.1039/d4na00086b. eCollection 2024 Apr 30. Nanoscale Adv. 2024. PMID: 38694472 Free PMC article. Review.
-
Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.Breast Cancer Res Treat. 2024 Jul;206(1):143-153. doi: 10.1007/s10549-024-07293-y. Epub 2024 Apr 5. Breast Cancer Res Treat. 2024. PMID: 38578521 Free PMC article.
-
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.Int J Clin Oncol. 2024 May;29(5):512-534. doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17. Int J Clin Oncol. 2024. PMID: 38493447
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous